Real-World ravulizumab data: hope for PNH patients in poland
NCT ID NCT06633536
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 64 Polish adults with paroxysmal nocturnal hemoglobinuria (PNH) who are taking ravulizumab as part of their routine care. Researchers will track blood markers like LDH and how many patients need blood transfusions over time. The goal is to see if the drug works as well in everyday life as it did in clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ravulizumab
- What this could lead to
- If successful, this study could confirm that ravulizumab works well in everyday practice for managing PNH, supporting its continued use.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It only includes 64 patients in Poland, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Bialystok, Poland
-
Research Site
Brzozów, Poland
-
Research Site
Bydgoszcz, Poland
-
Research Site
Gdansk, Poland
-
Research Site
Krakow, Poland
-
Research Site
Lodz, Poland
-
Research Site
Lublin, Poland
-
Research Site
Opole, Poland
-
Research Site
Szczecin, Poland
-
Research Site
Warsaw, Poland
-
Research Site
Wałbrzych, Poland